latest development

London (UK), Rehovot (IL), October 23rd, 2023

Vidac Pharma Holdings Plc. (SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ).

Vidac Pharma Holding Plc is proud to announce that Vidac Pharma Ltd, its operational arm received high appreciation for its Clinical Proposal for treatment of Non-Melanoma Skin Cancer (NMSC) and received the “Seal of Excellence” from the “Horizon Europe EIC Accelerator Program following evaluation by an international panel of independent experts and was recognized as a high-quality project proposal in a highly competitive evaluation process”. We are happy to share enclosed the Official announcement received. Dr. Max Herzberg, Chairman of the Board commented that “receiving such a distinction opens many opportunities to the Company in term of cooperation and funding as well as a follow up specific guidance of its management group offered by EIC selected experts”.


The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.

Vidac Pharma Holding PLC
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom


+972 (0)779300647